Drug

Larotrectinib

In clinical development

ClassNeurotrophic tyrosine kinase receptor inhibitorEmerging researchLate-stage development

Also known as Vitrakvi.

RxNorm2105628 ChEMBLCHEMBL3889654 ATCL01EX12UNIIPF9462I9HX

Research papers

Active clinical trials

Protein targets

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Molecular Analysis for Therapy Choice (MATCH)

Clinical trial2026-07-31Results expected Q4 2026 · ClinicalTrials.gov

MATCH Treatment Subprotocol Z1E: Larotrectinib (LOXO-101) in Patients With Tumors With NTRK Fusions

Clinical trial2026-05-05Results expected Q4 2026 · ClinicalTrials.gov

Neoadjuvant Umbrella Trial Directed by Next Generation Sequencing for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations (Without EGFR Sensitizing Mutations)

Clinical trial2026-04-21Results expected Q4 2027 · ClinicalTrials.gov

A Pilot and Surgical Study of Larotrectinib for Treatment of Children With Newly-Diagnosed High-Grade Glioma With NTRK Fusion

Clinical trial2026-03-18Results expected Q4 2026 · ClinicalTrials.gov

Larotrectinib to Enhance RAI Avidity in Patients With Differentiated Thyroid Cancer Harboring NTRK Fusions (LANTERN)

Clinical trial2025-11-14Results expected Q4 2026 · ClinicalTrials.gov

A Multicenter Prospective-Retrospective Real-World Study Evaluating Conversion-to-Surgery and Survival After Genotype-Matched Neoadjuvant Systemic Therapy in Locally Advanced Thyroid Carcinoma

Clinical trial2025-06-08Results expected Q4 2027 · ClinicalTrials.gov

Precision Medicine Applied to Locally Advanced Thyroid Cancer Using Tumor-derived Organoids and In-vitro Sensitivity Testing: a Phase 2a, Single-center, Open-label, and Non-comparative Study

Clinical trial2024-12-01Primary completion · ClinicalTrials.gov

A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors

Clinical trial2024-07-20Primary completion · ClinicalTrials.gov

Study to Investigate Outcome of Individualized Treatment Based on Pharmacogenomic Profiling & Ex Vivo Drug Sensitivity Testing of Patient-derived Organoids in Patients With Metastatic Colorectal Cancer

Clinical trial2023-02-21Results expected Q4 2038 · ClinicalTrials.gov

A Phase 1 Study of the Oral TRK Inhibitor Larotrectinib in Adult Patients With Solid Tumors

Clinical trial2021-04-09Completed · ClinicalTrials.gov

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Research2018-02-01The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Larotrectinib

Aliases & brands

Vitrakvi

RxNorm CUI

2105628

ChEMBL ID

CHEMBL3889654

ATC codes

L01EX12

UNII

PF9462I9HX

Primary mechanism

Neurotrophic tyrosine kinase receptor inhibitor

Pharmacology & targets

3 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

High affinity nerve growth factor receptor

NTRK1 · P04629

INHIBITORNeurotrophic tyrosine kinase receptor inhibitor

BDNF/NT-3 growth factors receptor

NTRK2 · Q16620

INHIBITORNeurotrophic tyrosine kinase receptor inhibitor

NT-3 growth factor receptor

NTRK3 · Q16288

INHIBITORNeurotrophic tyrosine kinase receptor inhibitor

Clinical trials

10 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2021

Active studies

Recruiting

Late-stage (III+)

Completed

PHASE DISTRIBUTIONn = 10

Early Phase 11Phase 11Phase 1 / 21Phase 26Phase 41

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Multicenter Prospective-Retrospective Real-World Study Evaluating Conversion-to-Surgery and Survival After Genotype-Matched Neoadjuvant Systemic Therapy in Locally Advanced Thyroid Carcinoma

Not yet recruitingPH IVFujian Medical Universityn=3352028

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase 1 Study of the Oral TRK Inhibitor Larotrectinib in Adult Patients With Solid Tumors

CompletedPH IBayern=752021

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

The New England journal of medicine · 2018 · 1,987 cites